
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Treating the Whole Patient dialogue explores the relationship between mental health and physical conditions. The discussion is moderated by Drs Jon W. Draud, Rakesh Jain, Vladimir Maletic and Charles Raison.
Featured posts:




